Compare Novo Nordisk A/S (NVO) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance

Novo Nordisk A/STrade

Invesco S&P 500 High Div Low Volatility ETFTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Novo Nordisk A/S trades at $45.08 (market cap $198.57B), while Invesco S&P 500 High Div Low Volatility ETF trades at $51.61. The key difference: Novo Nordisk A/S pays a 4.03% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none, and Invesco S&P 500 High Div Low Volatility ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.

	NVO	SPHD
Market Cap	$198.57B	—
Sector	Health	—
52-Week High	$63.98	$53.55
52-Week Low	$35.29	$46.96
Enterprise Value	$213.37B	—
Dividend Yield	4.03%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.

The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.

Invesco S&P 500 High Div Low Volatility ETF

SPHD trades at $51.96, down 0.65% on the day, with a technical outlook showing mixed signals—bullish oscillators but bearish moving averages. The ETF offers a high dividend yield, targeting income investors with low volatility exposure. Recent news highlights its role in retirement portfolios but notes potential yield traps without quality filters.

The outlook remains cautious due to valuation concerns and competition from peers like SCHD. Risks include underperformance in total returns and sensitivity to interest rate changes. Income-focused investors may find value, but growth-oriented holders should monitor fundamental weaknesses.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVO

Canada imposes retaliatory tariffs on $20B of U.S. goods, escalating trade tensions and impacting North American supply chains.Seeking Alpha · 2 days agoNeutral 4-Factor Dividend Growth Strategy slightly outperforms SCHD with 14.89% returns, testing new variants.Seeking Alpha · 3 days agoBullish View details →

SPHD

Invesco SPHD ETF offers high yield but underperforms peers due to quality issues and risk exposure.Seeking Alpha · 3 days agoBearish View details →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About Invesco S&P 500 High Div Low Volatility ETF

The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.